Sandoz's Multi-Switch Biosimilar Trials: A View To Interchangeability?
Executive Summary
Company's application development seems to be outpacing FDA's policy development in next step along the 351(k) pathway.
You may also be interested in...
Interchangeable Biosimilars: FDA Clarifies US Reference Not Mandatory For Studies
Draft guidance strongly recommends against it, but US FDA's Leah Christl says agency is willing to talk about using foreign-licensed comparators.
Interchangeable Biosimilars: FDA Clarifies US Reference Not Mandatory For Studies
Draft guidance strongly recommends against it, but US FDA's Leah Christl says agency is willing to talk about using foreign-licensed comparators.
Biosimilar Firms Fight Against 'Whisper Campaign' On Interchangeability
Industry calls for more education amid concerns that brand sales reps are encouraging providers to use only interchangeable products because they are better than biosimilars.